Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody

J Pediatr Gastroenterol Nutr. 2006 Feb;42(2):245-8. doi: 10.1097/01.mpg.0000189347.32796.c5.

Abstract

Fulminating acute ulcerative colitis (UC) is a potentially life threatening medical emergency. Up to 30% of individuals respond poorly to corticosteroids alone and second line medical or surgical therapies are indicated. We describe the successful use of chimeric anti-CD25 therapy in 4 such children poorly responsive to combined therapy with intravenous steroids and calcineurin inhibitors with a pretreatment predictive risk of colectomy of 85-100%. Clinical disease activity scores normalized within 72 hours of anti-CD25 administration and colonic histology provided evidence of mucosal healing within 10-14 days. None required emergency colectomy. Anti-CD25 is efficacious in fulminating UC and randomized placebo controlled trials appear indicated.

Publication types

  • Case Reports

MeSH terms

  • Acute Disease
  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Antibodies, Anti-Idiotypic / therapeutic use*
  • Calcineurin Inhibitors
  • Child
  • Colectomy
  • Colitis, Ulcerative / drug therapy*
  • Humans
  • Receptors, Interleukin-2 / immunology*
  • Risk Factors
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Adrenal Cortex Hormones
  • Antibodies, Anti-Idiotypic
  • Calcineurin Inhibitors
  • Receptors, Interleukin-2